Genetic sequencing; insurance; prohibition
HB2693 would restrict Arizona health insurance coverage for genetic sequencing when the sequencing is performed on equipment made by, or controlled by, companies domiciled in a “foreign adversary.” The bill applies this limitation across multiple insurance lines, including subscription contracts, health care service organizations, disability policies, group or blanket disability policies, and the state Medicaid program, subject to federal CMS approval for the Medicaid provision. It does not require insurers to cover genetic sequencing at all; instead, it allows them to deny or limit coverage for any valid reason, while specifically authorizing coverage limits tied to the origin or ownership of the sequencing device.
The bill also goes beyond insurance and imposes operational restrictions on health care institutions and research facilities. Those entities would be prohibited from using genetic sequencers or related software produced by foreign adversaries, Chinese military companies, or entities domiciled in or controlled by foreign adversaries. Prohibited equipment would have to be removed and replaced, annual compliance certification would be required, and genetic sequencing data would have to be stored in the United States with limits on remote access and cybersecurity requirements. The bill creates civil penalties for violations involving state monies and allows whistleblower reporting, as well as statutory damages for patients or research subjects whose genomes were sequenced using prohibited technology.
In practical terms, the bill would amend Arizona insurance and health care statutes in Titles 20 and 36 to add new restrictions and compliance duties tied to genetic sequencing technology. It would affect insurers, hospitals, research facilities, patients receiving genetic sequencing, and state-funded programs, while also creating a new definition of “foreign adversary” that includes several named countries and entities under their control. The Medicaid-related provision would only take effect if approved by the Centers for Medicare and Medicaid Services.
The overall sentiment reflected in the voting history appears mixed but generally supportive in the House and more divided in the Senate. The bill advanced through House committees and passed House third reading with a clear majority, but the Senate Health and Human Services Committee vote was narrower, and Senate third reading passed by only a small margin. That pattern suggests the bill had meaningful support, but not broad consensus.
The main point of contention appears to be the bill’s broad restriction on genetic sequencing technology based on foreign ownership or domicile, which could affect procurement, research operations, and access to testing. Supporters likely view the measure as a national-security and data-security safeguard, while opponents may be concerned about implementation costs, reduced technology options, and potential disruption to medical and research uses of genetic sequencing. The Medicaid and compliance provisions may also raise concerns about administrative burden and federal approval.
HB2693 would add new Arizona statutory restrictions on the use and insurance coverage of genetic sequencing technology, affecting insurers, health care institutions, research facilities, and state health programs. It would create new sections in the insurance code and health care regulation statutes that allow coverage limits for sequencing performed on devices made by companies tied to foreign adversaries, and it would prohibit certain institutions from using prohibited sequencers or software, require replacement of banned equipment, mandate annual compliance certification, and impose penalties and damages for violations. The bill also requires genetic sequencing data to be stored in the United States and adds cybersecurity and access-control requirements.
The bill appears to have received generally favorable but not unanimous support. It passed the House with a comfortable margin and advanced through committee, but Senate votes were tighter, indicating more skepticism or concern in the upper chamber. The lack of committee transcript material limits insight into the exact debate, but the voting pattern suggests the bill was viewed positively by many lawmakers while still drawing significant opposition.
The central controversy is the bill’s broad prohibition on genetic sequencing devices and software connected to “foreign adversaries,” especially China and other named countries, which could force institutions to replace existing technology and limit vendor choices. Critics are likely concerned about cost, feasibility, and possible effects on medical testing and research, while supporters likely emphasize security, supply-chain risk, and data protection. Additional points of contention include the penalties for violations, the requirement to store sequencing data in the United States, and the Medicaid provision’s dependence on CMS approval.